Oct 17 (Reuters) - SAGE Therapeutics Inc :
* SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT PORTFOLIO
* SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 33%
* SAGE THERAPEUTICS INC - REORGANIZATION TO IMPACT OVER 165 EMPLOYEES
* SAGE THERAPEUTICS INC - EXPECTS NON-RECURRING CHARGE OF $26M-$28M
* SAGE THERAPEUTICS INC - CHRIS BENECCHI TO BECOME CHIEF OPERATING OFFICER
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.